News for Vertex Pharmaceuticals Incorporated (VX1.DE)

The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce reductions.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Bernstein 41st Annual Strategic Decisions Conference May 30, 2025 8:00 AM ETCompany ParticipantsReshma...

Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain. Click to read why VRTX is a Buy.

-Collaboration brings together complementary capabilities to co-develop and co-commercialize SRSD107, a next generation, long-acting Factor XI (FXI) small inter

[url="]Vertex Pharmaceuticals Incorporated[/url] (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Susie Lisa,

Vertex Pharmaceuticals (VRTX) will participate in three major investor conferences in May and June 2025. Key executives, including CEO Dr. Reshma Kewalr

On CNBC's “Halftime Report Final Trades,” Brenda Vingiello, Chief Investment Officer of Sand Hill Global Advisors, picked Wynn Resorts, Limited WYNN as her ...

We recently published a list of 15 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other best stocks to buy according to Jim Simons’ Renaissance Technologies. Even after his passing in 2024, billionaire investor and […]

Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 2.54% (Institutional Shares) in the quarter compared to a 3.87% gain for the Russell 3000 Health Care Index (benchmark) and a 4.72% decline for the Russell […]

Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.

Vertex's diversification efforts are most visible in the progress of its pain management portfolio. Read why I rate VRTX stock a Buy.

-Initial CTX310â„¢ Phase 1 clinical data demonstrates dose-dependent decreases in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of u

U.S. stock futures were lower this morning, with the Dow futures falling over 200 points on Tuesday. Shares of Ichor Holdings, Ltd. ICHR fell sharply in today'...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

The following slide deck was published by Vertex Pharmaceuticals Incorporated in conjunction with their 2025 Q1 earnings call.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ETCompany ParticipantsSusie Lisa - SVP, IRReshma...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2025, and raised the low

Vertex Pharmaceuticals Incorporated VRTX will release earnings results for the first quarter, after the closing bell on Monday, May 5. Analysts expect the Bost...

On CNBC's “Halftime Report Final Trades,” Jim Lebenthal of Cerity Partners named Berkshire Hathaway Inc. BRK as his final trade ahead of its quarterly earni...